These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 30342309)

  • 1. A man with recurrent hypovolemic shock on anti-programmed cell death protein 1 treatment: Immune-related protein-losing enteropathy.
    Lee SY; Kim MH; Jang M; Park Y; Cho BC
    Eur J Cancer; 2018 Nov; 104():104-107. PubMed ID: 30342309
    [No Abstract]   [Full Text] [Related]  

  • 2. Autoimmune pancreatitis after nivolumab anti-programmed death receptor-1 treatment.
    Dehghani L; Mikail N; Kramkimel N; Soyer P; Lebtahi R; Mallone R; Larger E
    Eur J Cancer; 2018 Nov; 104():243-246. PubMed ID: 30454710
    [No Abstract]   [Full Text] [Related]  

  • 3. Acquired Hemophilia A After Nivolumab Therapy in a Patient With Metastatic Squamous Cell Carcinoma of the Lung Successfully Managed With Rituximab.
    Gokozan HN; Friedman JD; Schmaier AH; Downes KA; Farah LA; Reeves HM
    Clin Lung Cancer; 2019 Sep; 20(5):e560-e563. PubMed ID: 31311716
    [No Abstract]   [Full Text] [Related]  

  • 4. Dramatic response after anti PD1 treatment failure in a squamous cell carcinoma of the maxillary sinus.
    Larroquette M; Domblides C; Cousin S; De Gabory L; Dupin C; Ravaud A; Daste A
    Oral Oncol; 2018 Dec; 87():207-209. PubMed ID: 30343985
    [No Abstract]   [Full Text] [Related]  

  • 5. Hypothalamitis and severe hypothalamic dysfunction associated with anti-programmed cell death ligand 1 antibody treatment.
    Tshuma N; Glynn N; Evanson J; Powles T; Drake WM
    Eur J Cancer; 2018 Nov; 104():247-249. PubMed ID: 30377030
    [No Abstract]   [Full Text] [Related]  

  • 6. Efficacy and safety results from CheckMate 140, a phase 2 study of nivolumab for relapsed/refractory follicular lymphoma.
    Armand P; Janssens A; Gritti G; Radford J; Timmerman J; Pinto A; Mercadal Vilchez S; Johnson P; Cunningham D; Leonard JP; Rodig SJ; Martín-Regueira P; Sumbul A; Samakoglu S; Tang H; Ansell SM
    Blood; 2021 Feb; 137(5):637-645. PubMed ID: 32870269
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PD1 blockade with low-dose nivolumab in NK/T cell lymphoma failing L-asparaginase: efficacy and safety.
    Chan TSY; Li J; Loong F; Khong PL; Tse E; Kwong YL
    Ann Hematol; 2018 Jan; 97(1):193-196. PubMed ID: 28879531
    [No Abstract]   [Full Text] [Related]  

  • 8. Squamous Cell Carcinomas of the Head and Neck Cancer Response to Programmed Cell Death Protein-1 Targeting and Differential Expression of Immunological Markers: A Case Report.
    Merhi M; Raza A; Inchakalody VP; Nashwan AJJ; Allahverdi N; Krishnankutty R; Uddin S; Zar Gul AR; Al Homsi MU; Dermime S
    Front Immunol; 2018; 9():1769. PubMed ID: 30108590
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relapse of morphea during Nivolumab therapy for lung adenocarcinoma.
    Alegre-Sánchez A; Fonda-Pascual P; Saceda-Corralo D; de Las Heras-Alonso E
    Actas Dermosifiliogr; 2017; 108(1):69-70. PubMed ID: 27663405
    [No Abstract]   [Full Text] [Related]  

  • 10. Arterial Embolization During Programmed Death-1 Inhibitor Treatment: An Unexpected Finding.
    Dall'Olio FG; Sperandi F; Rihawi K; Gargiulo M; Melotti B; Brocchi S; Gelsomino F; Ardizzoni A
    J Thorac Oncol; 2018 Dec; 13(12):e247-e248. PubMed ID: 30467045
    [No Abstract]   [Full Text] [Related]  

  • 11. Nivolumab and its use in the second-line treatment of metastatic urothelial cancer.
    Raggi D; Necchi A; Giannatempo P
    Future Oncol; 2018 Nov; 14(26):2683-2690. PubMed ID: 29927336
    [TBL] [Abstract][Full Text] [Related]  

  • 12. What Have We Got to Lose?
    McNeil CM
    J Clin Oncol; 2016 Dec; 34(36):4443-4444. PubMed ID: 27998220
    [No Abstract]   [Full Text] [Related]  

  • 13. Spontaneous hematoma of the thigh associated with antiproteinase-3 antibody in a patient with metastatic squamous cell carcinoma treated with nivolumab.
    Keung YK; Hu EH
    J Oncol Pharm Pract; 2019 Jul; 25(5):1261-1264. PubMed ID: 29984627
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-PD-1 Drug (Nivolumab) May Induce Acute and Life-Threatening Pancreatitis in Lung Cancer Patient: A Case Report.
    Jiang R; Xu L; Huang Y; Fang C; Guo H; Li S; Wu J; Du Z
    Pancreas; 2018 Sep; 47(8):e53-e54. PubMed ID: 30113432
    [No Abstract]   [Full Text] [Related]  

  • 15. A case of checkpoint inhibitor-induced celiac disease.
    Alsaadi D; Shah NJ; Charabaty A; Atkins MB
    J Immunother Cancer; 2019 Aug; 7(1):203. PubMed ID: 31383006
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of dermatitis after PD-1/PD-L1 inhibitor therapy and association with multiple oncologic outcomes: A retrospective case-control study.
    Min Lee CK; Li S; Tran DC; Zhu GA; Kim J; Kwong BY; Chang ALS
    J Am Acad Dermatol; 2018 Dec; 79(6):1047-1052. PubMed ID: 29857011
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotherapy related colitis.
    Wagh VA; Sundaram S; Menon NN; Deodhar KK
    Indian J Pathol Microbiol; 2021; 64(4):857-859. PubMed ID: 34673627
    [No Abstract]   [Full Text] [Related]  

  • 18. Use of CAR-T cell therapy, PD-1 blockade, and their combination for the treatment of hematological malignancies.
    Song W; Zhang M
    Clin Immunol; 2020 May; 214():108382. PubMed ID: 32169439
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dermatomyositis associated with nivolumab therapy for melanoma: a case report and review of the literature.
    Messer A; Drozd B; Glitza IC; Lu H; Patel AB
    Dermatol Online J; 2020 Aug; 26(8):. PubMed ID: 32941716
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pembrolizumab-induced dermatomyositis in a patient with metastatic melanoma.
    Berger M; Legeay AL; Souci S; Streichenberger N; Thomas L; Dalle S
    Eur J Cancer; 2018 Nov; 104():227-230. PubMed ID: 30322679
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.